Status:
COMPLETED
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
Lead Sponsor:
AVAX Technologies
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune r...
Detailed Description
Patients with stage III or IV melanoma need to have at least one tumor mass of at least 2.5 cm (about 1 inch) diameter than can be removed for vaccine production. If the vaccine is successfully made a...
Eligibility Criteria
Inclusion
- stage III or IV melanoma at least one tumor mass of at least 2.5 cm diameter that can be excised to make vaccine good performance status
Exclusion
- brain metastases need for steroids or other immunosuppressive drugs positive PPD tests positive test for HIV, hepatitis B (antigen), or hepatitis C other serious medical illnesses
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00257465
Start Date
June 1 2005
End Date
June 1 2008
Last Update
December 3 2015
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona Cancer Center
Tucson, Arizona, United States
2
Pacific Oncology and Hematology Associates
San Diego, California, United States, 92024
3
University of Illinois School of Medicine
Chicago, Illinois, United States, 60612
4
University of Louisville
Louisville, Kentucky, United States